Iron Boride Nanostructures as Oral Acid-Responsive Hydrogen Donors for Alzheimer’s Disease Therapy
Molecular Pharmaceutics · 02.11.2026 · 23 (11) · 5288-5304
DOI: 10.1021/acs.molpharmaceut.6c00223 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 25.09.2026. Verfasst von Zetao Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Sciences and Oceanography, Guangdong Provincial Key Laboratory for Plant Epigenetics, Shenzhen University, Shenzhen518055, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Hydrogen, Nanostructures, Iron Compounds. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Shenzhen Science and Technology Program, Natural Science Foundation of Guangdong Province, Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) is a progressive neurodegenerative condition with complex causes. Despite extensive research, effective disease-modifying treatment options remain limited. Recent studies have indicated that hydrogen molecule (H2) possesses therapeutic potential for AD, and it is of vital importance to enhance the bioavailability of H2 in the gastrointestinal tract based on the gut−brain axis. In this work, we develop iron boride nanostructures (FBN) as a novel acid-responsive hydrogen-releasing material with a high hydrogen release capacity to enhance the H2 delivery efficacy towards the gastrointestinal tract for AD treatment. In male 5×FAD and 3×Tg-AD mice, oral FBN administration generated H2 under gastric conditions and was associated with AD-like behavioral and pathological improvements, including improved learning and memory and attenuation of neuronal and synaptic damage. FBN treatment was associated with increased synaptophysin (SYP) expression and dendritic spine density. Additionally, FBN treatment was associated with reduced amyloid-beta (Aβ) accumulation and attenuated tau pathology, two key pathological features of AD. FBN treatment was also associated with increased expression of mitochondrial fusion-related proteins and improved mitochondrial morphology. Furthermore, FBN treatment increased antioxidant defense-related proteins and reduced apoptosis-related markers, suggesting a possible enhancement of neuroprotective responses. In addition, FBN treatment induced changes in gut microbiota-related metabolites, suggesting a possible contribution of the gut−brain axis. These findings provide valuable insight into the mechanisms underlying the protective effects of hydrogen against AD and support the development of hydrogen-based therapies for slowing or preventing disease progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Life Sciences and Oceanography, Guangdong Provincial Key Laboratory for Plant Epigenetics, Shenzhen University, Shenzhen518055, China.
- Shenzhen Research Institute, Shanghai Jiao Tong University, Shenzhen518057, China.
- Shanghai Key Laboratory of Hydrogen Science & Center of Hydrogen Science, School of Materials Science and Engineering, Shanghai Jiao Tong University, Shanghai200240, China.
- Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, Shenzhen518055, China.
- Chemical Analysis & Physical Testing Institute, Shenzhen Center for Disease Control and Prevention, Shenzhen518055, China.
ORCID-Profile: Xiubo Du
Förderung
- Shenzhen Science and Technology Program
- Natural Science Foundation of Guangdong Province
- Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions
- National Natural Science Foundation of China (NSFC)
- Shenzhen-Hong Kong Institute of Brain Science−Shenzhen Fundamental Research Institutions
Zitieren
APA
Chen, Z., Chen, D., Zhang, J., Wang, C., Liu, J., Liang, Y., He, Q., & Du, X. (2026). Iron Boride Nanostructures as Oral Acid-Responsive Hydrogen Donors for Alzheimer’s Disease Therapy. Molecular Pharmaceutics, 23(11), 5288-5304. https://doi.org/10.1021/acs.molpharmaceut.6c00223
Vancouver
Chen Z, Chen D, Zhang J, Wang C, Liu J, Liang Y, et al. Iron Boride Nanostructures as Oral Acid-Responsive Hydrogen Donors for Alzheimer’s Disease Therapy. Molecular Pharmaceutics. 2026;23(11):5288-5304. doi:10.1021/acs.molpharmaceut.6c00223
BibTeX
@article{Chen2026,
author = {Chen, Zetao and Chen, Danyang and Zhang, Junjie and Wang, Chao and Liu, Jiaji and Liang, Yonglin and He, Qianjun and Du, Xiubo},
title = {Iron Boride Nanostructures as Oral Acid-Responsive Hydrogen Donors for Alzheimer’s Disease Therapy},
journal = {Molecular Pharmaceutics},
year = {2026},
volume = {23},
number = {11},
pages = {5288--5304},
doi = {10.1021/acs.molpharmaceut.6c00223}
}
EUVIMED